Claims for Patent: 4,966,888

Summary for Patent: 4,966,888

Title:	hCG-hLH receptor and hCG-hLH receptor-hCG complex as antigens, antibodies thereto and contraceptive vaccine
Abstract:	Purified hCG-hLH receptor, hCG-hLH receptor-hCG complex and combinations between their subunits as antigens, as well as antibodies thereto which are useful as a contraceptive vaccine.
Inventor(s):	Saxena; Brij B. (Englewood, NJ), Rathnam; Premila (Englewood Cliffs, NJ), Singh; Mukul (New York, NY)
Assignee:	Cornell Research Foundation, Inc. (Ithaca, NY)
Application Number:	06/910,554
Patent Claims:	1. An antigen capable of being administered to a host animal to selectively induce an antibody response comprising: (A) a first unit selected from the group consisting of (i) human chorionic gonadotropin, and (ii) a .beta.-subunit of human chorionic gonadotropin, and (B) a second unit comprising a purified receptor for human chorionic gonadotropin conjugated with said first unit, said antigen being capable of selectively inducing an antibody response to each of said first unit and second unit thereof. 2. The antigen of claim 1 wherein the antigen comprises the .beta.-subunit of human chorionic gonadotropin. 3. The antigen of claim 2 wherein the second unit of the antigen comprises a purified fraction of an extract containing the naturally-occurring receptor for human chorionic gonadotropin. 4. The antigen of claim 3 wherein the extract is of a plasma membrane of a corpus luteum of a species containing the receptor for human chorionic gonadotropin. 5. The antigen of claim 1 or claim 4 wherein the second unit is a substantially pure glycoprotein obtained from a naturally-occurring source of the common receptor for hLH and hCG and having the following characteristics: (a) being electrophoretically homogeneous; (b) a molecular weight of the aggregate of about 5.9 million .+-.10%: and (c) having specific binding capability for hLH and hCG. 6. The antigen of claim 5 wherein the glycoprotein has a specific binding capacity of at least 2,000 pM hCG/mg protein. 7. The antigen of claim 5 wherein the glycoprotein has the following additional characteristics: (a) an amino acid analysis (percent by weight .+-.10% as follows: (b) a carbohydrate composition comprising mannose, galactose, N-acetylglucosamine N-acetylgalactosamine and sialic acid. 8. The antigen of claims 1 or 4 wherein the second unit is a substantially pure glycoprotein obtained from a naturally-occurring source of the common receptor for hLH and hCG having the following characteristics: (a) being electrophoretically homogeneous; (b) a molecular weight of about 240,000 to 280,000.+-.10%: and (c) having specific binding capability for hLH and hCG. 9. The antigen of claims 1 or 4 wherein the second unit is a substantially pure glycoprotein obtained from a naturally-occurring source of the common receptor for hLH and hCG having the following characteristics: (a) being electrophoretically homogeneous; (b) a molecular weight of about 120,000 to 140,000.+-.10%: and (c) having specific binding capability for hLH and hCG. 10. The antigen of claims 1 or 4 wherein the second unit is a substantially pure glycoprotein obtained from a naturally-occurring source of the common receptor for hLH and hCG having the following characteristics: (a) being electrophoretically homogeneous; (b) a molecular weight of about 34,000 to 38,000.+-.10%; and (c) having specific binding capability for hLH and hCG. 11. The antigen of claims 1 or 4 wherein the second unit is a substantially pure glycoprotein obtained from a naturally-occurring source of the common receptor for hLH and hCG having the following characteristics: (a) being electrophoretically homogeneous; (b) a molecular weight of about 70,000 to 85,000.+-.10%; and (c) having specific binding capability for hLH and hCG. 12. A vaccine for preventing pregnancy comprising the antigen of any one of claims 1 through 4 and a pharmaceutically acceptable carrier. 13. A vaccine for preventing pregnancy comprising the antigen of claim 5 and a pharmaceutically acceptable carrier. 14. A vaccine for preventing pregnancy comprising the antigen of claim 6 and a pharmaceutically acceptable carrier. 15. A vaccine for preventing pregnancy comprising the antigen of claim 7 and a pharmaceutically acceptable carrier. 16. A vaccine for preventing pregnancy comprising the antigen of claim 8 and a pharmaceutically acceptable carrier. 17. A vaccine for preventing pregnancy comprising the antigen of claim 9 and a pharmaceutically acceptable carrier. 18. A vaccine for preventing pregnancy comprising the antigen of claim 10 and a pharmaceutically acceptable carrier. 19. A vaccine for preventing pregnancy comprising the antigen of claim 11 and a pharmaceutically acceptable carrier. 20. A vaccine for preventing pregnancy comprising in combination in an amount sufficient for preventing pregnancy (1) human chorionic gonadotropin or the .beta.-subunit of human chorionic gonadotropin as an antigen capable of selectively generating antibodies comprising determinants for human chorionic gonadotropin, and (2) a purified receptor for human chorionic gonadotropin as an antigen capable of selectively generating antibodies comprising determinants for the naturally-occurring receptor for human chorionic gonadotropin, and a pharmaceutically acceptable carrier. 21. A method for preventing pregnancy comprising administering to a female the vaccine of claim 20 in an amount effective for preventing pregnancy. 22. A vaccine for preventing pregnancy comprising in an amount effective for preventing pregnancy a purified naturally-occurring receptor for human chorionic gonadotropin as an antigen capable of selectively generating antibodies comprising determinants for the naturally-occurring receptor for human chorionic gonadotropin and a pharmaceutically acceptable carrier. 23. The vaccine for preventing pregnancy as claimed in claim 22, wherein said naturally-occurring receptor is prepared by the process comprising the steps of: (1) homogenizing a receptor source material in an aqueous medium to disperse the receptor in a liquid aqueous fraction; (2) separating membrane-bound protein containing the receptor from the liquid aqueous fraction; (3) dispersing the membrane-bound protein in an aqueous medium and extracting the aqueous medium with an organic solvent in which lipids are soluble to remove lipid from the aqueous phase; (4) separating the aqueous phase containing the receptor from the remainder of the product of step (3) and concentrating the aqueous phase; and (5) fractionating the aqueous phase based upon molecular weight to remove inert proteins and concentrating the receptor fraction. 24. The vaccine for preventing pregnancy as claimed in claim 23, wherein the process further comprises the steps of: (6) subjecting the receptor fraction to electrophoresis to separate said fraction from other remaining protein fractions; and (7) purifying the receptor fraction by subjecting it to immuno affinity chromatography. 25. The vaccine for preventing pregnancy of claims 22, 23, or 24 wherein the receptor for hCG is a glycoprotein having the following characteristics: (a) being electrophoretically homogeneous; (b) a molecular weight of the aggregate of about 5.9 million .+-.10%; and (c) having specific binding capability for hLH and hCG. 26. The vaccine for preventing pregnancy as claimed in claim 25 wherein the glycoprotein has a specific binding capacity of at least 2,000 pM hCG/mg protein. 27. The vaccine for preventing pregnancy as claimed in claim 25 wherein the glycoprotein has the following additional characteristics: (a) an amino acid analysis (percent by weight.+-.10%) as follows: (b) a carbohydrate composition comprising mannose, galactose, N-acetylglucosamine, N-acetylgalactosamine and sialic acid. 28. The vaccine for preventing pregnancy as claimed in claims 22, 23 or 24 wherein the receptor for hCG is a glycoprotein having the following characteristics: (a) being electrophoretically homogeneous; (b) a molecular weight of about 240,000 to 280,000.+-.10%; and (c) having specific binding capability for hLH and hCG. 29. The vaccine for preventing pregnancy as claimed in claims 22, 23 or 24 wherein the receptor for hCG is a glycoprotein having the following characteristics: (a) being electrophoretically homogeneous; (b) a molecular weight of about 120,000 to 140,000.+-.10%: and (c) having specific binding capability for hLH and hCG. 30. The vaccine for preventing pregnancy as claimed in claims 22, 23 or 24 wherein the receptor for hCG is a glycoprotein having the following characteristics: (a) being electrophoretically homogeneous; (b) a molecular weight of about 34,000 to 38.000.+-.10%; and (c) having specific binding capability for hLH and hCG. 31. The vaccine for preventing pregnancy as claimed in claims 22, 23 or 24 wherein the receptor for hCG is a glycoprotein having the following characteristics: (a) being electrophoretically homogeneous; (b) a molecular weight of about 70,000 to 85,000.+-.10%; and (c) having specific binding capability for hLH and hCG. 32. A process for preventing pregnancy comprising administering to a female the vaccine of any one of claims 22-24 in an amount sufficient for preventing pregnancy.

Details for Patent 4,966,888

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	January 15, 1974	4,966,888	2006-09-23
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	December 27, 1984	4,966,888	2006-09-23
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	February 15, 1985	4,966,888	2006-09-23
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	February 16, 1990	4,966,888	2006-09-23
Bel-mar Laboratories, Inc.	CHORIONIC GONADOTROPIN	chorionic gonadotropin	Injection	017054	March 26, 1974	4,966,888	2006-09-23
Fresenius Kabi Usa, Llc	CHORIONIC GONADOTROPIN	chorionic gonadotropin	For Injection	017067	March 05, 1973	4,966,888	2006-09-23